UDIO ISPITANIKA in English translation

• proportion of subjects

Examples of using Udio ispitanika in Croatian and their translations into English

Udio ispitanika s klinički značajnim porastom tjelesne težine(≥ 7%-tni porast od početne vrijednosti 21. dana ispitivanja) bio je 14,1% za asenapin 2, 5 mg dvaput na dan, 8,9% za asenapin
The proportion of subjects with clinically significant weight gain(≥ 7% weight gain from baseline at Day 21) was 14.1% for asenapine 2.5 mg twice daily, 8.9% for asenapine 5 mg twice daily, and 9.2% for asenapine 10 mg twice daily,

feritina(ng/ml) i udio ispitanika s odgovorom hemoglobina 35. dana(definiran kao udio ispitanika s povećanjem hemoglobina za najmanje 1, 0 g/dl) u svakoj liječenoj skupini u ispitivanjima 1,
as well as the proportion of subjects who were Hgb Responders at Day 35(defined as proportion of subjects with an increase in Hgb of at least 1.0 g/dl)

neznatno manji udio ispitanika oekuje da će zaštita ZO- a sprijeiti zlouporabu imena(87%),
while a slightly smaller proportion of respondents expect that protection will reduce abuse of the Slavonian kulen name(87%),

Nije bilo razlike između skupina u udjelu ispitanika s OPA titrom ≥ 1:8 za 7 čestih serotipova.
For the 7 common serotypes there were no differences between groups in the proportion of subjects with OPA titres≥ 1:8.

imali klinički značajno i statistički značajno smanjenje: udjela ispitanika s relapsom unutar 2 godine(primarna mjera ishoda ispitivanja 1) i godišnje stopa relapsa
the primary endpoint in Study 1, proportion of subjects relapsed at 2 years; and the primary endpoint in Study 2,

Udio ispitanika s rezultatom psorijaze vlasišta(ScPGA)
Proportion of subjects with Scalp Psoriasis PGA(ScPGA)

Udio ispitanika sa serokonverzijom do 7. i do 28. dana nakon posljednje imunizacije bio je sličan za oba rasporeda.
The proportion of subjects that seroconverted by 7 and by 28 days after the last immunisation was similar for both schedules.

U 12. tjednu udio ispitanika na eltrombopagu koji su prijavili bilo kakvo krvarenje smanjen je na polovicu od početnog 36.
At Week 12, the proportion of eltrombopag subjects reporting any bleeding was decreased to half of baseline 36.

Najniži udio ispitanika koji se s tom tvrdnjom slažu
The lowest share of respondents either agreeing totally

Udio ispitanika u kojih su se pojavili štetni događaji
The proportion of subjects experiencing adverse events(AE)

Klinički značajne egzacerbacije prijavio je jednak udio ispitanika(3/9) koji su primali placebo
The same proportion of subjects(3/9) receiving placebo and mepolizumab intravenously reported clinically significant exacerbations;

Udio ispitanika s ≥1 ciljnim zglobom na početku bio je manji u skupini koja je primala profilaksu u individualiziranim intervalima nego u skupini koja je primala profilaksu u tjednim intervalima 27,6% odnosno 57, 1.
There was a lower proportion of subjects in individualised interval prophylaxis with≥1 target joint at baseline than in weekly prophylaxis 27.6% and 57.1%, respectively.

Među bolesnicima u dobi od ≥ 65 godina, nuspojave povezane s deplecijom volumena i oštećenjem funkcije bubrega ili zatajenjem bubrega imao je veći udio ispitanika liječenih dapagliflozinom nego onih koji su primali placebo vidjeti dio 4.8.
In subjects≥ 65 years of age, a higher proportion of subjects treated with dapagliflozin had adverse reactions related to volume depletion and renal impairment or failure compared with placebo see section 4.8.

Međutim, kako je visok udio ispitanika(26%) zbog nedostatka djelotvornosti prekinuo s otvorenim ispitivanjima,
However, as a high proportion of subjects(26%) discontinued from the open-label studies due to lack of efficacy,

u usporedbi s ACWY-PS, veći udio ispitanika koji su primili cjepivo Menveo je imao hSBA ≥1:8 za serogrupe C,
compared with ACWY-PS, a higher proportion of subjects vaccinated with Menveo had hSBA≥1:8 for serogroups C, W135, and Y,

hipotenzije imao je veći udio ispitanika liječenih dapagliflozinom nego onih koji su uzimali placebo.
60 ml/min/1.73 m2), a higher proportion of subjects treated with dapagliflozin had adverse reactions of increase in creatinine, phosphorus, parathyroid hormone(PTH) and hypotension, compared with placebo.

FACT ispitivanje: Tijekom razdoblja provođenja profilakse u trajanju od 8 tjedana, zabilježen je veći udio ispitanika kojima je bilo potrebno liječenje akutnog napada gihta u skupini na febuksostatu 120 mg(36%),
Fact study: During the 8-week prophylaxis period, a greater proportion of subjects in the febuxostat 120 mg(36%) treatment group required treatment for a gout flare compared

Tijekom kliničkih ispitivanja ukupan udio ispitanika sa zloćudnim ili nespecificiranim tumorima bio je podjednak među bolesnicima liječenim dapagliflozinom( 1,
During clinical trials, the overall proportion of subjects with malignant or unspecified tumours was similar between those treated with dapagliflozin(1.50%) and placebo/comparator(1.50%),

Udio ispitanika s prosječnom tjednom učestalosti od tri ili više spontanih kompletnih pražnjenja
The proportion of patients with an average weekly frequency of≥3 Spontaneous Complete Bowel Movements(SCBMs)

Podaci o udjelu ispitanika koji su bili podvrgnuti kolektomiji u bilo kojem trenutku unutar 54 tjedna od prve infuzije ispitivanog lijeka prikupljeni su
The proportion of subjects who underwent colectomy at any time within 54 weeks following the first infusion of study agent were collected